Management Communication – C204
Nasaquil Executive Summary
Nasaquil Exclusive
Mel Co has been granted the exclusive contract to distribute the newest over the counter flu treatment
Nasaquil. This revolutionary new medication will change the way the influenza virus is treated for
everyone. Weather a consumer is diagnosed by medical professional or just suspects that they have the
flu, they can begin treatment to lessen the symptoms and shorten the duration of the illness.
Target
According to estimates by the CDC, October 1, 2018, thru February 16, 2019, there were approximately
nineteen million flu related illnesses in the United States. Around eight to nine million of these turned
into flu-related medical visits. Our target consumer is these nineteen million who had the flu and
specifically the eight to nine million who went into the doctor or ER for diagnosis. Because of our
companies extensive relationships in the medical community there is great anticipation for the success
of this new medication.
Risk and Reward
There are several risks associated with this new product launch. Two specifically- one, our business
partner Pruhart Tech and availability of the specialized refrigerated shipping containers required for
overnight shipping of the medication. We will work with Pruhart Tech to ensure their manufacturing
operation will be able to handle demand. Second, due to the limited clinical trials of a new medication’s
efficacy in a small group of patients over a limited amount of time, we do not yet know long-term
product efficacy rates or effects. We will closely monitor all customer complaints and handle each one
on a case-by-case basis. The rewards will be great also. The most obvious being, we have the exclusive
contract to distribute the latest cutting edge over the counter flu medication approved for use in the US.
With nineteen million diagnosed cases of the flu, if priced accordingly the profit could potentially range
in the hundreds of millions to billions of dollars per year. Second, if managed properly Melo Co could
have the opportunity to expand its reach beyond the US and begin to grow our international business
unit at a faster rate.
Conclusion
In conclusion, we are on the cusp of a revolution in the treatment of the influenza virus. If our obstacles
are managed properly, we have the potential to help millions of consumers fight the flu and grow our
business expediential numbers.
Nasaquil Executive Summary
Nasaquil Exclusive
Mel Co has been granted the exclusive contract to distribute the newest over the counter flu treatment
Nasaquil. This revolutionary new medication will change the way the influenza virus is treated for
everyone. Weather a consumer is diagnosed by medical professional or just suspects that they have the
flu, they can begin treatment to lessen the symptoms and shorten the duration of the illness.
Target
According to estimates by the CDC, October 1, 2018, thru February 16, 2019, there were approximately
nineteen million flu related illnesses in the United States. Around eight to nine million of these turned
into flu-related medical visits. Our target consumer is these nineteen million who had the flu and
specifically the eight to nine million who went into the doctor or ER for diagnosis. Because of our
companies extensive relationships in the medical community there is great anticipation for the success
of this new medication.
Risk and Reward
There are several risks associated with this new product launch. Two specifically- one, our business
partner Pruhart Tech and availability of the specialized refrigerated shipping containers required for
overnight shipping of the medication. We will work with Pruhart Tech to ensure their manufacturing
operation will be able to handle demand. Second, due to the limited clinical trials of a new medication’s
efficacy in a small group of patients over a limited amount of time, we do not yet know long-term
product efficacy rates or effects. We will closely monitor all customer complaints and handle each one
on a case-by-case basis. The rewards will be great also. The most obvious being, we have the exclusive
contract to distribute the latest cutting edge over the counter flu medication approved for use in the US.
With nineteen million diagnosed cases of the flu, if priced accordingly the profit could potentially range
in the hundreds of millions to billions of dollars per year. Second, if managed properly Melo Co could
have the opportunity to expand its reach beyond the US and begin to grow our international business
unit at a faster rate.
Conclusion
In conclusion, we are on the cusp of a revolution in the treatment of the influenza virus. If our obstacles
are managed properly, we have the potential to help millions of consumers fight the flu and grow our
business expediential numbers.
